Table 5.
Application of PD-L1 antibodies in cancer combination therapy in 2019.
| PD-L1 Ab | Combination | Involved trial records |
|---|---|---|
| Atezolizumab (Tecentriq) | 40 (Total) | |
| Radiation | 6 | |
| Chemotherapy | 6 | |
| Regulatory inhibitors | 2 | |
| Receptor inhibitors | 13 | |
| Immunoregulator antibody (CD73) | 1 | |
| Immunoregulator antibody (PD-1) | 2 | |
| Immunoregulator antibody subtotal | 7 | |
| PARP inhibitor | 3 | |
| Avelumab (Bavencio) | 21 (Total) | |
| Radiation | 5 | |
| Chemotherapy | 6 | |
| Regulatory inhibitors | 1 | |
| Receptor inhibitors | 5 | |
| Immunoregulator antibody (IDO) | 2 | |
| Immunoregulator antibody subtotal | 4 | |
| Durvalumab (Imfinzi) | 56 (Total) | |
| Radiation | 14 | |
| Chemotherapy | 18 | |
| Regulatory inhibitors | 8 | |
| Receptor inhibitors | 9 | |
| Immunoregulator antibody (CTLA-4) | 12 | |
| Immunoregulator antibody (CD73) | 6 | |
| Immunoregulator antibody subtotal | 24 | |
| PARP inhibitor | 3 |